Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.

@article{Yancey2010DistributionMA,
  title={Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.},
  author={Mark F Yancey and Dawn A Merritt and Julie A. White and Susan A. Marsh and Charles W. Locuson},
  journal={Journal of veterinary pharmacology and therapeutics},
  year={2010},
  volume={33 2},
  pages={154-61}
}
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, has been developed for the treatment of mast cell tumors in dogs. An overview of the distribution, metabolism, and excretion of toceranib phosphate in dogs is presented. When [(14)C]-toceranib was orally administered to dogs, the majority of the radioactivity (92%) was excreted in feces and only a small portion (7%) was excreted in urine. Seven days after a single 3… CONTINUE READING